[go: up one dir, main page]

MX2008012017A - Pirazoles como inhibidores de 11-beta-hsd1. - Google Patents

Pirazoles como inhibidores de 11-beta-hsd1.

Info

Publication number
MX2008012017A
MX2008012017A MX2008012017A MX2008012017A MX2008012017A MX 2008012017 A MX2008012017 A MX 2008012017A MX 2008012017 A MX2008012017 A MX 2008012017A MX 2008012017 A MX2008012017 A MX 2008012017A MX 2008012017 A MX2008012017 A MX 2008012017A
Authority
MX
Mexico
Prior art keywords
hsd
pyrazoles
beta
compounds
substituents
Prior art date
Application number
MX2008012017A
Other languages
English (en)
Inventor
Nader Fotouhi
Jefferson Wright Tilley
Paul Gillespie
Qiang Zhang
Sherrie Lynn Pietranico-Cole
Pamela Loreen Rossman
Nancy-Ellen Haynes
Nathan Robert Scott
Kshitij Chhabilbhai Thakkar
Robert Alan Goodnow Jr
Kevin Richard Guertin
Lida Qi
Michael Paul Myers
Kevin William Anderson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38430507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008012017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2008012017A publication Critical patent/MX2008012017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporcionan compuestos de la fórmula (I) así como sales farmacéuticamente aceptables de los mismos, en donde los sustituyentes tienen los significados definidos en la descripción. Estos compuestos y las composiciones farmacéuticas que los contienen son útiles para el tratamiento de enfermedades tales como la diabetes mellitus del tipo II y el síndrome metabólico. (ver fórmula).
MX2008012017A 2006-03-22 2007-03-12 Pirazoles como inhibidores de 11-beta-hsd1. MX2008012017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78483106P 2006-03-22 2006-03-22
US87527406P 2006-12-15 2006-12-15
PCT/EP2007/052269 WO2007107470A2 (en) 2006-03-22 2007-03-12 Pyrazoles as 11-beta-hsd-1

Publications (1)

Publication Number Publication Date
MX2008012017A true MX2008012017A (es) 2008-10-01

Family

ID=38430507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012017A MX2008012017A (es) 2006-03-22 2007-03-12 Pirazoles como inhibidores de 11-beta-hsd1.

Country Status (29)

Country Link
US (1) US7728029B2 (es)
EP (2) EP1999114B1 (es)
JP (1) JP5031817B2 (es)
KR (2) KR101077366B1 (es)
CN (1) CN101405270B (es)
AR (1) AR059983A1 (es)
AU (1) AU2007228887B2 (es)
BR (1) BRPI0708974A2 (es)
CA (1) CA2645856C (es)
CR (1) CR10288A (es)
DK (1) DK1999114T3 (es)
EC (1) ECSP088747A (es)
ES (1) ES2548002T3 (es)
HR (1) HRP20151078T1 (es)
HU (1) HUE026011T2 (es)
IL (1) IL193900A (es)
MA (1) MA30344B1 (es)
MX (1) MX2008012017A (es)
MY (1) MY149622A (es)
NO (1) NO341746B1 (es)
NZ (1) NZ570973A (es)
PL (1) PL1999114T3 (es)
PT (1) PT1999114E (es)
RS (1) RS54216B1 (es)
RU (2) RU2402517C2 (es)
SG (1) SG155961A1 (es)
SI (1) SI1999114T1 (es)
TW (2) TWI351403B (es)
WO (1) WO2007107470A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
CN101578257A (zh) * 2006-11-02 2009-11-11 盐野义制药株式会社 羟基金刚烷胺的制造方法
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20100144717A1 (en) * 2006-12-15 2010-06-10 Janelle Comita-Prevoir 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
JP4671369B2 (ja) * 2007-05-18 2011-04-13 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体
WO2009010416A2 (en) * 2007-07-17 2009-01-22 F. Hoffmann-La Roche Ag Inhibitors of 11b-hydroxysteroid dehydrogenase
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2072497A1 (de) * 2007-12-21 2009-06-24 Bayer CropScience AG Verfahren zum Herstellen von 2-Fluoracyl-3-amino-acrylsäure-Derivaten
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
JP2012516327A (ja) * 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
JP5686413B2 (ja) * 2009-12-22 2015-03-18 塩野義製薬株式会社 アダマンタンアミン誘導体
CN102127583A (zh) * 2010-01-19 2011-07-20 上海博康精细化工有限公司 一种反式对氨基金刚烷醇的制备方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2604591A4 (en) * 2010-08-09 2015-07-22 Shionogi & Co PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2012176717A1 (ja) 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
JP2013023476A (ja) * 2011-07-22 2013-02-04 Sagami Chemical Research Institute ５−フルオロ−１ｈ−ピラゾール−４−カルボン酸類の製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
MX2014006350A (es) * 2011-11-30 2014-06-23 Bayer Ip Gmbh Derivados de n-bicicloalquil- y n-tricicloalquil-(tio)carboxamida fungicidas.
CN102633659B (zh) * 2012-02-23 2013-12-04 浙江普洛康裕制药有限公司 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法
ES2656012T3 (es) 2013-02-06 2018-02-22 Bayer Cropscience Aktiengesellschaft Derivados de pirazol sustituidos con halógeno como pesticidas
CN105637152B (zh) 2013-07-24 2017-11-28 沃尔沃建造设备有限公司 用于工程机械的液压回路
CN105934429B (zh) * 2013-11-27 2022-03-04 拜耳动物保健有限责任公司 制备5-氟-1h-吡唑的方法
US9845312B2 (en) 2013-11-27 2017-12-19 Bayer Cropscience Aktiengesellschaft Process for the preparation of 5-fluoro-1H-pyrazoles
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
CN105315284A (zh) * 2014-07-23 2016-02-10 上海医药工业研究院 阿拉格列汀中间体的制备方法
CN104961698A (zh) * 2015-07-13 2015-10-07 佛山市赛维斯医药科技有限公司 末端硝基取代的三氮唑亚砜类化合物、其制备方法及其用途
KR101759874B1 (ko) * 2015-08-07 2017-07-21 코스맥스 주식회사 11β-hydroxysteroid dehydrogenase type 1의 활성을 저해하는 화합물을 포함하는 화장료 조성물 또는 피부 외용제 조성물
MA56030A (fr) * 2019-05-24 2022-04-06 Fmc Corp Pyrrolidinones substituées par un pyrazole utilisés comme herbicides
WO2024118348A1 (en) * 2022-11-29 2024-06-06 Mirati Therapeutics, Inc. Processes and intermediates for synthesis of mrtx0902

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH307629A (de) 1952-05-23 1955-06-15 Ag J R Geigy Verfahren zur Herstellung eines monosubstituierten Hydrazins.
DE2635841C2 (de) 1976-08-10 1983-02-24 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von Alkoxymethylenmalonsäurenitrilen
US4620865A (en) 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
WO1986002641A1 (fr) 1984-10-29 1986-05-09 Sumitomo Chemical Company, Limited Derives de pyrazolecarboxamide, procede de preparation et bactericides les contenant en tant qu'ingredients efficaces
US4792565A (en) 1986-04-24 1988-12-20 Mitsui Toatsu Chemicals, Inc. Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
DE19615976A1 (de) 1996-04-22 1997-10-23 Basf Ag Mittel und Verfahren zur Bekämpfung von Schadpilzen
US5948777A (en) 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SI1201128T1 (sl) 1997-12-18 2006-02-28 Basf Ag Fungicidne zmesi na osnovi piridinkarboksamidnih spojin
WO1999067235A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Co., Ltd. Five-membered ring compounds
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19853827A1 (de) 1998-11-21 2000-05-25 Aventis Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL136360A (en) 1999-06-18 2004-08-31 Mitsui Chemicals Inc History 5 - Aminopyrazole-4 - Carboxylate and processes for their preparation
ES2546386T3 (es) 1999-07-20 2015-09-23 Dow Agrosciences, Llc Amidas aromáticas heterocíclicas fungicidas y sus composiciones, métodos de uso y preparación
DE60039115D1 (de) 1999-08-20 2008-07-17 Dow Agrosciences Llc Fungizide heterocyclische aromatische amide und deren zusammensetzungen, verfahren zu deren anwendung und herstellung
AU780572B2 (en) 1999-10-18 2005-04-07 University Of Connecticut, The Pyrazole derivatives as cannabinoid receptor antagonists
US6096898A (en) 1999-10-22 2000-08-01 Dow Agrosciences Llc One pot synthesis of 1,2,4-triazoles
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2002003410A (ja) 2000-06-27 2002-01-09 Fuji Photo Film Co Ltd 芳香族ハロゲン化物の製造方法。
CA2430061A1 (en) 2000-11-28 2002-06-06 Pfizer Products Inc. Preparation of sodium-hydrogen exchanger type-1 inhibitors
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
DE10161978A1 (de) 2001-12-17 2003-06-26 Bayer Ag Verfahren zur Herstellung von 2-Halogenacyl-3-amino-acrylsäure-derivate
WO2003051845A1 (en) 2001-12-19 2003-06-26 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (en) 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
PL374971A1 (en) 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
RU2360910C2 (ru) * 2002-12-20 2009-07-10 Мерк Энд Ко., Инк. Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1
CN100372838C (zh) 2003-02-17 2008-03-05 弗·哈夫曼-拉罗切有限公司 哌啶-苯磺酰胺衍生物
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
WO2005009973A1 (en) 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
WO2005000793A1 (ja) 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２位置換シクロアルキルカルボン酸誘導体
AU2004265299B2 (en) 2003-08-07 2008-05-01 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8362264B2 (en) 2003-08-22 2013-01-29 Dendreon Corporation Compositions and methods for the treatment of disease associated with Trp-p8 expression
HU227684B1 (en) * 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
IN240644B (es) 2004-01-28 2010-05-28 Mitsui Chemicals Inc
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
WO2006031806A2 (en) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones as therapeutic agents
WO2006035967A1 (en) 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
EP1928840B1 (en) * 2005-04-05 2011-08-10 F. Hoffmann-La Roche AG 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
CN101312951A (zh) * 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物

Also Published As

Publication number Publication date
RU2402517C2 (ru) 2010-10-27
ES2548002T3 (es) 2015-10-13
WO2007107470A2 (en) 2007-09-27
CA2645856C (en) 2011-09-20
EP1999114B1 (en) 2015-07-22
AU2007228887B2 (en) 2012-02-02
EP2295411A1 (en) 2011-03-16
CA2645856A1 (en) 2007-09-27
MA30344B1 (fr) 2009-04-01
WO2007107470A3 (en) 2007-11-08
US20070225280A1 (en) 2007-09-27
RU2010119648A (ru) 2011-11-27
HRP20151078T1 (hr) 2015-11-20
NZ570973A (en) 2011-11-25
TW200806651A (en) 2008-02-01
NO20083863L (no) 2008-12-03
PT1999114E (pt) 2015-10-16
RU2008141434A (ru) 2010-04-27
HK1130780A1 (en) 2010-01-08
US7728029B2 (en) 2010-06-01
AR059983A1 (es) 2008-05-14
CN101405270A (zh) 2009-04-08
KR20110007258A (ko) 2011-01-21
TW201103916A (en) 2011-02-01
EP1999114A2 (en) 2008-12-10
HUE026011T2 (en) 2016-05-30
PL1999114T3 (pl) 2015-12-31
CR10288A (es) 2008-10-06
ECSP088747A (es) 2008-10-31
BRPI0708974A2 (pt) 2011-06-21
SG155961A1 (en) 2009-10-29
NO341746B1 (no) 2018-01-15
KR101077366B1 (ko) 2011-10-26
JP5031817B2 (ja) 2012-09-26
TWI351403B (en) 2011-11-01
DK1999114T3 (en) 2015-08-03
RS54216B1 (sr) 2015-12-31
CN101405270B (zh) 2013-01-16
SI1999114T1 (sl) 2015-10-30
MY149622A (en) 2013-09-13
KR20090005015A (ko) 2009-01-12
AU2007228887A1 (en) 2007-09-27
RU2470016C2 (ru) 2012-12-20
JP2009530343A (ja) 2009-08-27
IL193900A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
MY149622A (en) Pyrazoles as 11-beta-hsd-1
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
TW200643013A (en) Pyrazoles
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
MX2011012122A (es) Derivados de tiofeno.
TW200806311A (en) Neuropeptide-2 receptor-agonists
TW200833663A (en) Therapeutic agents
MX2007010072A (es) Derivados de piperidina antibacterianos.
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2008002062A (es) Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen.
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2009013501A (es) Compuestos piperidinicos y sus usos.
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
WO2008006795A3 (en) Indole compounds
TW200738627A (en) Trialkylsilyl-indoles
TW200639156A (en) New compounds
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FG Grant or registration